That's our eco-friendly packaging company right?
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
That's our eco-friendly packaging company right?
Correct Sir!
Shares of Li Auto Inc. fell 3.2% in premarket trading Tuesday, in the wake of the China-based electric vehicle maker's announcement overnight that January deliveries grew more than four-fold from a year ago. Li's report comes a day after fellow China-based EV makers reported January deliveries, in which Nio Inc.'s jumped 352% and Xpeng Inc.'s hiked up 470%. Li's deliveries rose 356% to 5,379 Li ONE SUVs. Separately, the company said it established a new research and development center in Shanghai, aimed a developing EV technologies, such as high-voltage platforms, ultra-fast charging technologies and autonomous driving technologies. Li's stock has rallied 40.0% over the past three months through Monday, while Nio shares have climbed 71.0%, XPeng's stock has soared 138% and the S&P 500 has gained 14.0%.
A) InterPrivate Acquisition Corp. (IPV)
NYSE - NYSE Delayed Price. Currency in USD
15.22+0.46 (+3.12%)
At close: 4:00PM EST
15.55 +0.33 (2.17%)
This is the Spac that turns into the 4D LIDAR co with the two former Apple guys.....
NYSE - NYSE Delayed Price. Currency in USD
15.22+0.46 (+3.12%)
At close: 4:00PM EST
15.55 +0.33 (2.17%)
This is the Spac that turns into the 4D LIDAR co with the two former Apple guys.....
AGTC-- This gets a little tricky. I have noticed a new trend in investing in which raising funds and diluting shareholders is now a good thing!
Lets go through this:
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the pricing of its previously announced underwritten public offering of 16,741,573 shares of its common stock, together with accompanying warrants to purchase 8,370,786 shares of common stock. The common stock will be sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock sold. The combined offering price to the public of each share of common stock and accompanying warrant is $4.45. The warrants must be exercised in integral multiples of two and will have an exercise price of $6.00 per share, will be immediately exercisable and will have a term of five years from the date of issuance. The gross proceeds to AGTC from this offering are expected to be approximately $74.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by AGTC. All of the securities are being sold by AGTC. The offering is expected to close on or about February 1, 2021, subject to customary closing conditions.
Stifel, Wells Fargo Securities and MTS Health Partners are acting as joint book-running managers of the offering, H.C. Wainwright & Co. is acting as lead manager for the offering and Roth Capital Partners is acting as co-manager for the offering.
AGTC intends to use the net proceeds from this offering, together with other available funds, to fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa (XLRP) program and its ongoing Phase 1/2 clinical trials in its Achromatopsia (ACHM) program, and for working capital and other general corporate purposes.////
Lets go through this:
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the pricing of its previously announced underwritten public offering of 16,741,573 shares of its common stock, together with accompanying warrants to purchase 8,370,786 shares of common stock. The common stock will be sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock sold. The combined offering price to the public of each share of common stock and accompanying warrant is $4.45. The warrants must be exercised in integral multiples of two and will have an exercise price of $6.00 per share, will be immediately exercisable and will have a term of five years from the date of issuance. The gross proceeds to AGTC from this offering are expected to be approximately $74.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by AGTC. All of the securities are being sold by AGTC. The offering is expected to close on or about February 1, 2021, subject to customary closing conditions.
Stifel, Wells Fargo Securities and MTS Health Partners are acting as joint book-running managers of the offering, H.C. Wainwright & Co. is acting as lead manager for the offering and Roth Capital Partners is acting as co-manager for the offering.
AGTC intends to use the net proceeds from this offering, together with other available funds, to fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa (XLRP) program and its ongoing Phase 1/2 clinical trials in its Achromatopsia (ACHM) program, and for working capital and other general corporate purposes.////
AGTC IS THE GUMMY OF THE DAY!
8x8 Inc
8x8 Inc (NYSE:EGHT), a Campbell, California-based provider of various telecommunication software solutions for businesses, government agencies and other public organizations worldwide.
8x8 invested $35.83 million for the purchase of property, plant and equipment in full fiscal 2020, which marked an impressive increase from total spending of $5.83 million in full fiscal 2015.
Morningstar analysts estimate an earnings growth rate of 76.30% on higher sales of $526.30 million for full fiscal 2021 (up 17.90% year over year), followed by earnings growth of 142.90% on higher sales of $611.99 million for full fiscal 2022 (up 16.30% year over year).
8x8 Inc (NYSE:EGHT), a Campbell, California-based provider of various telecommunication software solutions for businesses, government agencies and other public organizations worldwide.
8x8 invested $35.83 million for the purchase of property, plant and equipment in full fiscal 2020, which marked an impressive increase from total spending of $5.83 million in full fiscal 2015.
Morningstar analysts estimate an earnings growth rate of 76.30% on higher sales of $526.30 million for full fiscal 2021 (up 17.90% year over year), followed by earnings growth of 142.90% on higher sales of $611.99 million for full fiscal 2022 (up 16.30% year over year).
I see Wainright raised their target on it today lol.AGTC IS THE GUMMY OF THE DAY!
$18-$24
Imagine that huh, since they are lead manager on the dilution.
Its an orphan drug for Achromatopsia.
The potential market in the US and EU is 27,000 cases.
Chart's pretty ugly.
Gummy of the day?
Naaaa.
You're outvoted 3-1
Nasstassia and Yulia proxied their vote to me. All the big words and pictures in this filing confused them:
http://archive.fast-edgar.com/20210201/AE22622CZM2RVJZA222N2ZYORUOTYZ22Z232/
I like this one. A lot.8x8 Inc
8x8 Inc (NYSE:EGHT), a Campbell, California-based provider of various telecommunication software solutions for businesses, government agencies and other public organizations worldwide.
8x8 invested $35.83 million for the purchase of property, plant and equipment in full fiscal 2020, which marked an impressive increase from total spending of $5.83 million in full fiscal 2015.
Morningstar analysts estimate an earnings growth rate of 76.30% on higher sales of $526.30 million for full fiscal 2021 (up 17.90% year over year), followed by earnings growth of 142.90% on higher sales of $611.99 million for full fiscal 2022 (up 16.30% year over year).
It goes in the ira, but I want an overall market correction to get some.
EDIT:
SNAP, crackle, pop.
Snap hit an all-time high earlier btw.
Now now easy Yulia.... she always gets upset with those Edgar pulls.... Do you know one year I invested in Edgar I think they went private....
The upgrade I saw was this one--
Applied Genetic price target raised to $35 from $30 at Roth Capital 09:22 AGTC Roth Capital analyst Zegbeh Jallah raised the firm's price target on Applied Genetic to $35 from $30 and keeps a Buy rating on the shares. The analyst notes that Applied Genetic press-released "encouraging" data from its Phase 1/2 studies of AGTC-402 in Achromatopsia patients that typically have little-to-no photoreceptor function, and experience extreme light discomfort. The update from these patients with CNGB3 and CNGA3 mutations was the very first quantitative evidence of visual sensitivity improvements, Jallah adds. More updates are expected in 2021, but the analyst views this is as a "strong" indication of AGTC-402's efficacy potential, and more broadly Applied Genetic's gene therapy platform.
And I don't think HC was lead underwriter....
Applied Genetic $60M Spot Secondary re-offered at $4.45 16:44 AGTC Stifel, Wells Fargo Securities and MTS Health Partners are acting as joint book-running managers of the offering.
But the way I see it is there is probably a trade here.... The potential market is bigger I think...
Ulcerative colitis is a chronic and idiopathic inflammatory disease.
Ulcerative colitis has an incidence of 9 to 20 cases per100,000persons per year. Its prevalence is 156 to 291 cases per100,000persons per year. Compared to Crohn disease, ulcerative colitis has a greater prevalence in adults.
I think the US has 1 million+ people are affected with ulcerative colitis (UC)
/ / / /
I almost bought this name when you told me to find a pipe or plumber company....
Tetra Tech surges after winning NYSE compliance, Evercore double-upgrade
Feb. 02, 2021 9:27 AM ETTETRA Technologies, Inc. (TTI
The upgrade I saw was this one--
Applied Genetic price target raised to $35 from $30 at Roth Capital 09:22 AGTC Roth Capital analyst Zegbeh Jallah raised the firm's price target on Applied Genetic to $35 from $30 and keeps a Buy rating on the shares. The analyst notes that Applied Genetic press-released "encouraging" data from its Phase 1/2 studies of AGTC-402 in Achromatopsia patients that typically have little-to-no photoreceptor function, and experience extreme light discomfort. The update from these patients with CNGB3 and CNGA3 mutations was the very first quantitative evidence of visual sensitivity improvements, Jallah adds. More updates are expected in 2021, but the analyst views this is as a "strong" indication of AGTC-402's efficacy potential, and more broadly Applied Genetic's gene therapy platform.
And I don't think HC was lead underwriter....
Applied Genetic $60M Spot Secondary re-offered at $4.45 16:44 AGTC Stifel, Wells Fargo Securities and MTS Health Partners are acting as joint book-running managers of the offering.
But the way I see it is there is probably a trade here.... The potential market is bigger I think...
Ulcerative colitis is a chronic and idiopathic inflammatory disease.
Ulcerative colitis has an incidence of 9 to 20 cases per100,000persons per year. Its prevalence is 156 to 291 cases per100,000persons per year. Compared to Crohn disease, ulcerative colitis has a greater prevalence in adults.
I think the US has 1 million+ people are affected with ulcerative colitis (UC)
/ / / /
I almost bought this name when you told me to find a pipe or plumber company....
Tetra Tech surges after winning NYSE compliance, Evercore double-upgrade
Feb. 02, 2021 9:27 AM ETTETRA Technologies, Inc. (TTI
- Tetra Technologies(NYSE:TTI)+24.3%pre-market after saying it received formal notice from the NYSE that it hasregained fullcompliancewith the Exchange's minimum average closing share price listing requirement.
- The notice confirms the company's average closing share price for the consecutive 30-trading days ended Jan. 31 was above the NYSE's minimum $1/share requirement.
- Also, Evercore ISI upgrades shares two notches to Outperform from Underperform with a $3 price target, hiked from $1, citing lithium and carbon-capture opportunities.